Cargando…
Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence
Since 2005, an abundance of targeted agents has been approved for the treatment of metastatic renal cell carcinoma (mRCC), without any specification as to what may be the most optimal first-line and second-line sequence. Hence, our objective was to critically examine the evidence supporting the use...
Autores principales: | Sun, Maxine, Larcher, Alessandro, Karakiewicz, Pierre I |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219683/ https://www.ncbi.nlm.nih.gov/pubmed/25378943 http://dx.doi.org/10.2147/IJNRD.S48496 |
Ejemplares similares
-
Current Options for Second-Line Systemic Therapy in Metastatic Renal Cell Carcinoma
por: Mitsogiannis, Iraklis C., et al.
Publicado: (2022) -
Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis
por: Mori, Keiichiro, et al.
Publicado: (2020) -
Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
por: Géczi, Lajos, et al.
Publicado: (2020) -
Second-Line Treatment of Metastatic Renal Cell Carcinoma in the Era of Predictive Biomarkers
por: Parosanu, Andreea Ioana, et al.
Publicado: (2023) -
Current and emerging therapies for first line treatment of metastatic clear cell renal cell carcinoma
por: Serzan, Michael T., et al.
Publicado: (2021)